1. Home
  2. MNRO vs ADCT Comparison

MNRO vs ADCT Comparison

Compare MNRO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monro Inc.

MNRO

Monro Inc.

HOLD

Current Price

$15.82

Market Cap

472.5M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.21

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNRO
ADCT
Founded
1957
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Automotive Aftermarket
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
472.5M
431.2M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
MNRO
ADCT
Price
$15.82
$3.21
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$16.00
$7.75
AVG Volume (30 Days)
1.1M
968.6K
Earning Date
05-27-2026
05-04-2026
Dividend Yield
6.69%
N/A
EPS Growth
113.64
30.86
EPS
0.03
N/A
Revenue
$1,157,176,000.00
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.59
$66.49
P/E Ratio
$525.67
N/A
Revenue Growth
N/A
14.85
52 Week Low
$13.51
$2.55
52 Week High
$23.91
$4.98

Technical Indicators

Market Signals
Indicator
MNRO
ADCT
Relative Strength Index (RSI) 43.32 36.52
Support Level $14.90 $3.06
Resistance Level $18.24 $4.73
Average True Range (ATR) 0.99 0.16
MACD -0.03 0.01
Stochastic Oscillator 20.60 17.36

Price Performance

Historical Comparison
MNRO
ADCT

About MNRO Monro Inc.

Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: